CyberLiver joins prestigious DigitalHealth.London Accelerator programme

London (03 Jul, 2023): Today CyberLiver is proud to announce they are one of the 17 digital health companies selected for DigitalHealth.London’s Accelerator programme. The companies selected for the Accelerator 2023/24 programme have digital solutions or services that have the highest potential to meet London’s NHS and social care challenges.

Now in its seventh consecutive year, the DigitalHealth.London Accelerator is funded by Health Innovation Network (HIN) through its Office for Life Sciences funding and its partners, including CW+. In addition, the Accelerator will receive £185k from the UK Government through the UK Shared Prosperity Fund for some aspects of this programme.

RSara Nelson, Programme Director, DigitalHealth.London, said: “We are delighted to announce the 17 digital health companies joining our seventh DigitalHealth.London Accelerator cohort. The application process for this year’s programme was extremely competitive and as such, the final 17 companies truly are the ones to watch in the digital health space. We look forward to working with them over the next year to support the NHS and social care through digital transformation.”

Ravi Kumar, Founder and CEO of CyberLiver, said: "We are excited to join this prestigious program to accelerate adoption of CyberLiver digital therapeutic solutions within the NHS. CyberLiver is committed to halting or reversing liver disease through their innovative solutions, enhancing patients' quality of life and alleviating the cost burden on the healthcare systems. We look forward to providing these valuable new treatment options in clinical practice to people living with liver disease."

DigitalHealth.London’s Accelerator aims to speed up the adoption of technology in London’s NHS, relieving high pressure on services and empowering patients to manage their health. The Accelerator has previously supported 143 high potential digital health companies across six cohorts. It works with the companies over a 12-month period, giving bespoke support and advice, a programme of expert-led workshops and events, and brokering meaningful connections between innovators and NHS organisations with specific challenges. The companies successful in getting onto the Accelerator programme have been chosen through a rigorous and highly competitive selection

For more on CyberLiver, please visit:

About CyberLiver® CyberLiver are re-inventing liver care pathways through digital medicine platform with a mission to become a global leader in digital medicine for Liver disease.

AlcoChange® is intended to reduce alcohol use and maintain abstinence in individuals with established alcohol-related liver disease (ArLD).

A CirrhoCare® is intended for assisted diagnosis, recommendations and therapeutic intervention for the management of new complications of decompensated cirrhosis.

For more on CyberLiver, please visit:

Enquiries, contact:

Ravan Boddu

Chief Operating Officer

[email protected]

+1 (408) 499-9034